VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q43014233 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241221010837.0
008 241221nneanz||abbn n and d
035 ‎‡a (WKP)Q43014233‏
024 ‎‡a 0000-0003-1231-4894‏ ‎‡2 orcid‏
024 ‎‡a 6603893235‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q43014233‏
100 0 ‎‡a Juan P de Torres‏ ‎‡9 ast‏ ‎‡9 es‏ ‎‡9 sl‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Juan P de Torres‏ ‎‡c researcher‏ ‎‡9 en‏
400 0 ‎‡a Juan P de Torres‏ ‎‡c onderzoeker‏ ‎‡9 nl‏
670 ‎‡a Author's 5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging‏
670 ‎‡a Author's A simple algorithm for the identification of clinical COPD phenotypes.‏
670 ‎‡a Author's Agreement between a simple dyspnea-guided treatment algorithm for stable COPD and the GOLD guidelines: a pilot study‏
670 ‎‡a Author's Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest.‏
670 ‎‡a Author's Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT.‏
670 ‎‡a Author's Association of IL-6 gene polymorphisms and COPD in a Spanish population.‏
670 ‎‡a Author's BODE Index: A Good Quality of Life Marker in Chronic Obstructive Pulmonary Disease Patients‏
670 ‎‡a Author's C-reactive protein levels and clinically important predictive outcomes in stable COPD patients‏
670 ‎‡a Author's C-reactive protein levels and survival in patients with moderate to very severe COPD.‏
670 ‎‡a Author's Changes and clinical consequences of smoking cessation in COPD patients: a prospective analysis from the CHAIN cohort.‏
670 ‎‡a Author's Chronic Obstructive Pulmonary Disease‏
670 ‎‡a Author's Chronic Obstructive Pulmonary Disease (COPD) as a disease of early aging: Evidence from the EpiChron Cohort.‏
670 ‎‡a Author's Chronic obstructive pulmonary disease in Women. Is it Different?‏
670 ‎‡a Author's Clinical application of the COPD assessment test: longitudinal data from the COPD History Assessment in Spain (CHAIN) cohort.‏
670 ‎‡a Author's Clinical Features of Smokers With Radiological Emphysema But Without Airway Limitation.‏
670 ‎‡a Author's Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease‏
670 ‎‡a Author's Comparison of 2017 and 2015 Global Initiative for Obstructive Lung Disease: Impact on Grouping and Outcomes.‏
670 ‎‡a Author's COPD comorbidities network.‏
670 ‎‡a Author's Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort.‏
670 ‎‡a Author's Diagnostic yield of electromagnetic navigation bronchoscopy is highly dependent on the presence of a Bronchus sign on CT imaging: results from a prospective study‏
670 ‎‡a Author's Differences between GesEPOC and GOLD in 2017‏
670 ‎‡a Author's Differential Effect of Modified Medical Research Council Dyspnea, COPD Assessment Test, and Clinical COPD Questionnaire for Symptoms Evaluation Within the New GOLD Staging and Mortality in COPD.‏
670 ‎‡a Author's Disease progression in young patients with COPD: rethinking the Fletcher and Peto model‏
670 ‎‡a Author's Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD‏
670 ‎‡a Author's Distribution and Outcomes of a Phenotype-Based Approach to Guide COPD Management: Results from the CHAIN Cohort‏
670 ‎‡a Author's Distribution and prognostic validity of the new Global Initiative for Chronic Obstructive Lung Disease grading classification.‏
670 ‎‡a Author's Electromyographic validation of the mouth pressure-time index: a noninvasive assessment of inspiratory muscle load‏
670 ‎‡a Author's Emphysema phenotypes and lung cancer risk‏
670 ‎‡a Author's Emphysema presence, severity, and distribution has little impact on the clinical presentation of a cohort of patients with mild to moderate COPD.‏
670 ‎‡a Author's Epicardial adipose tissue in patients with chronic obstructive pulmonary disease.‏
670 ‎‡a Author's Erratum: New GOLD classification: longitudinal data on group assignment‏
670 ‎‡a Author's Erratum to: Telomere shortening and accelerated aging in COPD: findings from the BODE cohort‏
670 ‎‡a Author's Evaluation of micro-CT for emphysema assessment in mice: comparison with non-radiological techniques.‏
670 ‎‡a Author's Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: a pilot study‏
670 ‎‡a Author's External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study‏
670 ‎‡a Author's FDG Uptake and the Diagnostic Yield of Transbronchial Needle Aspiration‏
670 ‎‡a Author's Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study.‏
670 ‎‡a Author's Gas exchange and breathing pattern in women with postmenopausal bone fragility‏
670 ‎‡a Author's Gender and chronic obstructive pulmonary disease in high-risk smokers.‏
670 ‎‡a Author's Gender and COPD in patients attending a pulmonary clinic‏
670 ‎‡a Author's Gender and respiratory factors associated with dyspnea in chronic obstructive pulmonary disease.‏
670 ‎‡a Author's Gender associated differences in determinants of quality of life in patients with COPD: a case series study‏
670 ‎‡a Author's Gender differences in plasma biomarker levels in a cohort of COPD patients: a pilot study‏
670 ‎‡a Author's Genome Expression Profiling-Based Identification and Administration Efficacy of Host-Directed Antimicrobial Drugs against Respiratory Infection by Nontypeable Haemophilus influenzae.‏
670 ‎‡a Author's Identification of COPD Patients at High Risk for Lung Cancer Mortality Using the COPD-LUCSS-DLCO.‏
670 ‎‡a Author's IL-8 gene variants are associated with lung function decline and multidimensional BODE index in COPD patients but not with disease susceptibility: a validation study‏
670 ‎‡a Author's Immunomodulating effects of glatiramer acetate and its potential role in pulmonary tuberculosis reactivation‏
670 ‎‡a Author's Improving selection criteria for lung cancer screening. The potential role of emphysema.‏
670 ‎‡a Author's Increased expression of A Proliferation-inducing Ligand (APRIL) in lung leukocytes and alveolar epithelial cells in COPD patients with non small cell lung cancer: a possible link between COPD and lung cancer?‏
670 ‎‡a Author's Inflammatory and repair serum biomarker pattern: association to clinical outcomes in COPD.‏
670 ‎‡a Author's Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease‏
670 ‎‡a Author's Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer.‏
670 ‎‡a Author's Is COPD a Progressive Disease? A Long Term Bode Cohort Observation‏
670 ‎‡a Author's Longitudinal assessment in COPD patients: multidimensional variability and outcomes‏
670 ‎‡a Author's Longitudinal study of a mouse model of chronic pulmonary inflammation using breath hold gated micro-CT‏
670 ‎‡a Author's Low-dose Volumetric Computed Tomography for Quantification of Emphysema in Asymptomatic Smokers Participating in an Early Lung Cancer Detection Trial‏
670 ‎‡a Author's Lung Cancer and Emphysema.‏
670 ‎‡a Author's Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score.‏
670 ‎‡a Author's Lung cancer in patients with chronic obstructive pulmonary disease-- incidence and predicting factors‏
670 ‎‡a Author's Lung cancer screening: fourteen year experience of the Pamplona early detection program (P-IELCAP).‏
670 ‎‡a Author's Lung Cancer Screening: The Balance between Harm and Benefit‏
670 ‎‡a Author's Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease‏
670 ‎‡a Author's Multicomponent indices to predict survival in COPD: the COCOMICS study.‏
670 ‎‡a Author's Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD.‏
670 ‎‡a Author's Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD.‏
670 ‎‡a Author's Prognostic assessment in COPD without lung function: the B-AE-D indices.‏
670 ‎‡a Author's Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE.‏
670 ‎‡a Author's Prognostic Validation Using GesEPOC 2017 Severity Criteria‏
670 ‎‡a Author's Prospective comparison of non-invasive risk markers of major cardiovascular events in COPD patients‏
670 ‎‡a Author's Pulmonary arterial enlargement predicts long-term survival in COPD patients.‏
670 ‎‡a Author's Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease.‏
670 ‎‡a Author's Relationship between azithromycin susceptibility and administration efficacy for nontypeable Haemophilus influenzae respiratory infection‏
670 ‎‡a Author's Response to "Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients" ‏
670 ‎‡a Author's Robust, standardized quantification of pulmonary emphysema in low dose CT exams‏
670 ‎‡a Author's Sex differences in mortality in patients with COPD.‏
670 ‎‡a Author's Sex, forced expiratory volume in 1 s decline, body weight change and C-reactive protein in COPD patients‏
670 ‎‡a Author's Should age be part of multidimensional indices of risk in chronic obstructive pulmonary disease?‏
670 ‎‡a Author's Simplifying the guidelines: The 10 COPD commandments‏
670 ‎‡a Author's Telomere length, COPD and emphysema as risk factors for lung cancer.‏
670 ‎‡a Author's Telomere shortening and accelerated aging in COPD: findings from the BODE cohort.‏
670 ‎‡a Author's The 6-min walk distance in healthy subjects: reference standards from seven countries‏
670 ‎‡a Author's The 6-min walking distance: long-term follow up in patients with COPD.‏
670 ‎‡a Author's The effect of radiographic emphysema in assessing lung cancer risk‏
670 ‎‡a Author's The Global Burden of Pulmonary Diseases: Most Prevalent Problems and Opportunities for Improvement‏
670 ‎‡a Author's The importance of symptoms in the longitudinal variability of clusters in COPD patients: A validation study‏
670 ‎‡a Author's The neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers for lung cancer development‏
670 ‎‡a Author's The Prevalence of Obstructive Lung Disease in a Lung Cancer Screening Cohort: Analysis of the National Lung Screening Trial-American College of Radiology Image Network Cohort‏
670 ‎‡a Author's The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort‏
670 ‎‡a Author's Time to desaturation in the 6-min walking distance test predicts 24-hour oximetry in COPD patients with a PO2 between 60 and 70mmHg‏
670 ‎‡a Author's TNFA-863 polymorphism is associated with a reduced risk of Chronic Obstructive Pulmonary Disease: A replication study‏
670 ‎‡a Author's Trabecular bone score in active or former smokers with and without COPD‏
670 ‎‡a Author's What pulmonologists think about the asthma-COPD overlap syndrome‏
909 ‎‡a (orcid) 0000000312314894‏ ‎‡9 1‏
909 ‎‡a (scopus) 6603893235‏ ‎‡9 1‏
919 ‎‡a differentialeffectofmodifiedmedicalresearchcouncildyspneacopdassessmenttestandclinicalcopdquestionnaireforsymptomsevaluationwithinthenewgoldstagingandmortalityincopd‏ ‎‡A Differential Effect of Modified Medical Research Council Dyspnea, COPD Assessment Test, and Clinical COPD Questionnaire for Symptoms Evaluation Within the New GOLD Staging and Mortality in COPD.‏ ‎‡9 1‏
919 ‎‡a 5proteinbasedsignatureforresectablelungsquamouscellcarcinomaimprovestheprognosticperformanceofthetnmstaging‏ ‎‡A 5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging‏ ‎‡9 1‏
919 ‎‡a simplealgorithmfortheidentificationofclinicalcopdphenotypes‏ ‎‡A A simple algorithm for the identification of clinical COPD phenotypes.‏ ‎‡9 1‏
919 ‎‡a agreementbetweenasimpledyspneaguidedtreatmentalgorithmforstablecopdandthegoldguidelinesapilotstudy‏ ‎‡A Agreement between a simple dyspnea-guided treatment algorithm for stable COPD and the GOLD guidelines: a pilot study‏ ‎‡9 1‏
919 ‎‡a assessingtherelationshipbetweenlungcancerriskandemphysemadetectedonlowdosectofthechest‏ ‎‡A Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest.‏ ‎‡9 1‏
919 ‎‡a assessmentofindeterminatepulmonarynodulesdetectedinlungcancerscreeningdiagnosticaccuracyoffdgpetct‏ ‎‡A Assessment of indeterminate pulmonary nodules detected in lung cancer screening: Diagnostic accuracy of FDG PET/CT.‏ ‎‡9 1‏
919 ‎‡a associationofil6genepolymorphismsandcopdinaspanishpopulation‏ ‎‡A Association of IL-6 gene polymorphisms and COPD in a Spanish population.‏ ‎‡9 1‏
919 ‎‡a bodeindexagoodqualityoflifemarkerinchronicobstructivepulmonarydiseasepatients‏ ‎‡A BODE Index: A Good Quality of Life Marker in Chronic Obstructive Pulmonary Disease Patients‏ ‎‡9 1‏
919 ‎‡a 100reactiveproteinlevelsandclinicallyimportantpredictiveoutcomesinstablecopdpatients‏ ‎‡A C-reactive protein levels and clinically important predictive outcomes in stable COPD patients‏ ‎‡9 1‏
919 ‎‡a 100reactiveproteinlevelsandsurvivalinpatientswithmoderatetoveryseverecopd‏ ‎‡A C-reactive protein levels and survival in patients with moderate to very severe COPD.‏ ‎‡9 1‏
919 ‎‡a changesandclinicalconsequencesofsmokingcessationincopdpatientsaprospectiveanalysisfromthechaincohort‏ ‎‡A Changes and clinical consequences of smoking cessation in COPD patients: a prospective analysis from the CHAIN cohort.‏ ‎‡9 1‏
919 ‎‡a chronicobstructivepulmonarydisease‏ ‎‡A Chronic Obstructive Pulmonary Disease‏ ‎‡9 1‏
919 ‎‡a chronicobstructivepulmonarydiseasecopdasadiseaseofearlyagingevidencefromtheepichroncohort‏ ‎‡A Chronic Obstructive Pulmonary Disease (COPD) as a disease of early aging: Evidence from the EpiChron Cohort.‏ ‎‡9 1‏
919 ‎‡a chronicobstructivepulmonarydiseaseinwomenisitdifferent‏ ‎‡A Chronic obstructive pulmonary disease in Women. Is it Different?‏ ‎‡9 1‏
919 ‎‡a clinicalapplicationofthecopdassessmenttestlongitudinaldatafromthecopdhistoryassessmentinspainchaincohort‏ ‎‡A Clinical application of the COPD assessment test: longitudinal data from the COPD History Assessment in Spain (CHAIN) cohort.‏ ‎‡9 1‏
919 ‎‡a clinicalfeaturesofsmokerswithradiologicalemphysemabutwithoutairwaylimitation‏ ‎‡A Clinical Features of Smokers With Radiological Emphysema But Without Airway Limitation.‏ ‎‡9 1‏
919 ‎‡a comorbiditiesandriskofmortalityinpatientswithchronicobstructivepulmonarydisease‏ ‎‡A Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease‏ ‎‡9 1‏
919 ‎‡a comparisonof2017and2015globalinitiativeforobstructivelungdiseaseimpactongroupingandoutcomes‏ ‎‡A Comparison of 2017 and 2015 Global Initiative for Obstructive Lung Disease: Impact on Grouping and Outcomes.‏ ‎‡9 1‏
919 ‎‡a copdcomorbiditiesnetwork‏ ‎‡A COPD comorbidities network.‏ ‎‡9 1‏
919 ‎‡a definingtheasthmacopdoverlapsyndromeinacopdcohort‏ ‎‡A Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort.‏ ‎‡9 1‏
919 ‎‡a diagnosticyieldofelectromagneticnavigationbronchoscopyishighlydependentonthepresenceofabronchussignonctimagingresultsfromaprospectivestudy‏ ‎‡A Diagnostic yield of electromagnetic navigation bronchoscopy is highly dependent on the presence of a Bronchus sign on CT imaging: results from a prospective study‏ ‎‡9 1‏
919 ‎‡a differencesbetweengesepocandgoldin‏ ‎‡A Differences between GesEPOC and GOLD in 2017‏ ‎‡9 1‏
919 ‎‡a diseaseprogressioninyoungpatientswithcopdrethinkingthefletcherandpetomodel‏ ‎‡A Disease progression in young patients with COPD: rethinking the Fletcher and Peto model‏ ‎‡9 1‏
919 ‎‡a distanceandoxygendesaturationduringthe6minwalktestaspredictorsoflongtermmortalityinpatientswithcopd‏ ‎‡A Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD‏ ‎‡9 1‏
919 ‎‡a distributionandoutcomesofaphenotypebasedapproachtoguidecopdmanagementresultsfromthechaincohort‏ ‎‡A Distribution and Outcomes of a Phenotype-Based Approach to Guide COPD Management: Results from the CHAIN Cohort‏ ‎‡9 1‏
919 ‎‡a distributionandprognosticvalidityofthenewglobalinitiativeforchronicobstructivelungdiseasegradingclassification‏ ‎‡A Distribution and prognostic validity of the new Global Initiative for Chronic Obstructive Lung Disease grading classification.‏ ‎‡9 1‏
919 ‎‡a electromyographicvalidationofthemouthpressuretimeindexanoninvasiveassessmentofinspiratorymuscleload‏ ‎‡A Electromyographic validation of the mouth pressure-time index: a noninvasive assessment of inspiratory muscle load‏ ‎‡9 1‏
919 ‎‡a emphysemaphenotypesandlungcancerrisk‏ ‎‡A Emphysema phenotypes and lung cancer risk‏ ‎‡9 1‏
919 ‎‡a emphysemapresenceseverityanddistributionhaslittleimpactontheclinicalpresentationofacohortofpatientswithmildtomoderatecopd‏ ‎‡A Emphysema presence, severity, and distribution has little impact on the clinical presentation of a cohort of patients with mild to moderate COPD.‏ ‎‡9 1‏
919 ‎‡a epicardialadiposetissueinpatientswithchronicobstructivepulmonarydisease‏ ‎‡A Epicardial adipose tissue in patients with chronic obstructive pulmonary disease.‏ ‎‡9 1‏
919 ‎‡a erratumnewgoldclassificationlongitudinaldataongroupassignment‏ ‎‡A Erratum: New GOLD classification: longitudinal data on group assignment‏ ‎‡9 1‏
919 ‎‡a erratumtotelomereshorteningandacceleratedagingincopdfindingsfromthebodecohort‏ ‎‡A Erratum to: Telomere shortening and accelerated aging in COPD: findings from the BODE cohort‏ ‎‡9 1‏
919 ‎‡a evaluationofmicroctforemphysemaassessmentinmicecomparisonwithnonradiologicaltechniques‏ ‎‡A Evaluation of micro-CT for emphysema assessment in mice: comparison with non-radiological techniques.‏ ‎‡9 1‏
919 ‎‡a exploringtheimpactofscreeningwithlowdosectonlungcancermortalityinmildtomoderatecopdpatientsapilotstudy‏ ‎‡A Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: a pilot study‏ ‎‡9 1‏
919 ‎‡a externalvalidationandrecalculationofthecodexindexincopdpatientsa3ciapluscohortstudy‏ ‎‡A External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study‏ ‎‡9 1‏
919 ‎‡a fdguptakeandthediagnosticyieldoftransbronchialneedleaspiration‏ ‎‡A FDG Uptake and the Diagnostic Yield of Transbronchial Needle Aspiration‏ ‎‡9 1‏
919 ‎‡a findingthebestthresholdsoffev1anddyspneatopredict5yearsurvivalincopdpatientsthecocomicsstudy‏ ‎‡A Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study.‏ ‎‡9 1‏
919 ‎‡a gasexchangeandbreathingpatterninwomenwithpostmenopausalbonefragility‏ ‎‡A Gas exchange and breathing pattern in women with postmenopausal bone fragility‏ ‎‡9 1‏
919 ‎‡a genderandchronicobstructivepulmonarydiseaseinhighrisksmokers‏ ‎‡A Gender and chronic obstructive pulmonary disease in high-risk smokers.‏ ‎‡9 1‏
919 ‎‡a genderandcopdinpatientsattendingapulmonaryclinic‏ ‎‡A Gender and COPD in patients attending a pulmonary clinic‏ ‎‡9 1‏
919 ‎‡a genderandrespiratoryfactorsassociatedwithdyspneainchronicobstructivepulmonarydisease‏ ‎‡A Gender and respiratory factors associated with dyspnea in chronic obstructive pulmonary disease.‏ ‎‡9 1‏
919 ‎‡a genderassociateddifferencesindeterminantsofqualityoflifeinpatientswithcopdacaseseriesstudy‏ ‎‡A Gender associated differences in determinants of quality of life in patients with COPD: a case series study‏ ‎‡9 1‏
919 ‎‡a genderdifferencesinplasmabiomarkerlevelsinacohortofcopdpatientsapilotstudy‏ ‎‡A Gender differences in plasma biomarker levels in a cohort of COPD patients: a pilot study‏ ‎‡9 1‏
919 ‎‡a genomeexpressionprofilingbasedidentificationandadministrationefficacyofhostdirectedantimicrobialdrugsagainstrespiratoryinfectionbynontypeablehaemophilusinfluenzae‏ ‎‡A Genome Expression Profiling-Based Identification and Administration Efficacy of Host-Directed Antimicrobial Drugs against Respiratory Infection by Nontypeable Haemophilus influenzae.‏ ‎‡9 1‏
919 ‎‡a identificationofcopdpatientsathighriskforlungcancermortalityusingthecopdlucssdlco‏ ‎‡A Identification of COPD Patients at High Risk for Lung Cancer Mortality Using the COPD-LUCSS-DLCO.‏ ‎‡9 1‏
919 ‎‡a 8genevariantsareassociatedwithlungfunctiondeclineandmultidimensionalbodeindexincopdpatientsbutnotwithdiseasesusceptibilityavalidationstudy‏ ‎‡A IL-8 gene variants are associated with lung function decline and multidimensional BODE index in COPD patients but not with disease susceptibility: a validation study‏ ‎‡9 1‏
919 ‎‡a immunomodulatingeffectsofglatirameracetateanditspotentialroleinpulmonarytuberculosisreactivation‏ ‎‡A Immunomodulating effects of glatiramer acetate and its potential role in pulmonary tuberculosis reactivation‏ ‎‡9 1‏
919 ‎‡a improvingselectioncriteriaforlungcancerscreeningthepotentialroleofemphysema‏ ‎‡A Improving selection criteria for lung cancer screening. The potential role of emphysema.‏ ‎‡9 1‏
919 ‎‡a increasedexpressionofaproliferationinducingligandaprilinlungleukocytesandalveolarepithelialcellsincopdpatientswithnonsmallcelllungcancerapossiblelinkbetweencopdandlungcancer‏ ‎‡A Increased expression of A Proliferation-inducing Ligand (APRIL) in lung leukocytes and alveolar epithelial cells in COPD patients with non small cell lung cancer: a possible link between COPD and lung cancer?‏ ‎‡9 1‏
919 ‎‡a inflammatoryandrepairserumbiomarkerpatternassociationtoclinicaloutcomesincopd‏ ‎‡A Inflammatory and repair serum biomarker pattern: association to clinical outcomes in COPD.‏ ‎‡9 1‏
919 ‎‡a inspiratorytototallungcapacityratiopredictsmortalityinpatientswithchronicobstructivepulmonarydisease‏ ‎‡A Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease‏ ‎‡9 1‏
919 ‎‡a investigationofcomplementactivationproductc4dasadiagnosticandprognosticbiomarkerforlungcancer‏ ‎‡A Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer.‏ ‎‡9 1‏
919 ‎‡a iscopdaprogressivediseasealongtermbodecohortobservation‏ ‎‡A Is COPD a Progressive Disease? A Long Term Bode Cohort Observation‏ ‎‡9 1‏
919 ‎‡a longitudinalassessmentincopdpatientsmultidimensionalvariabilityandoutcomes‏ ‎‡A Longitudinal assessment in COPD patients: multidimensional variability and outcomes‏ ‎‡9 1‏
919 ‎‡a longitudinalstudyofamousemodelofchronicpulmonaryinflammationusingbreathholdgatedmicroct‏ ‎‡A Longitudinal study of a mouse model of chronic pulmonary inflammation using breath hold gated micro-CT‏ ‎‡9 1‏
919 ‎‡a lowdosevolumetriccomputedtomographyforquantificationofemphysemainasymptomaticsmokersparticipatinginanearlylungcancerdetectiontrial‏ ‎‡A Low-dose Volumetric Computed Tomography for Quantification of Emphysema in Asymptomatic Smokers Participating in an Early Lung Cancer Detection Trial‏ ‎‡9 1‏
919 ‎‡a lungcancerandemphysema‏ ‎‡A Lung Cancer and Emphysema.‏ ‎‡9 1‏
919 ‎‡a lungcancerinpatientswithchronicobstructivepulmonarydiseasedevelopmentandvalidationofthecopdlungcancerscreeningscore‏ ‎‡A Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score.‏ ‎‡9 1‏
919 ‎‡a lungcancerinpatientswithchronicobstructivepulmonarydiseaseincidenceandpredictingfactors‏ ‎‡A Lung cancer in patients with chronic obstructive pulmonary disease-- incidence and predicting factors‏ ‎‡9 1‏
919 ‎‡a lungcancerscreening14yearexperienceofthepamplonaearlydetectionprogrampielcap‏ ‎‡A Lung cancer screening: fourteen year experience of the Pamplona early detection program (P-IELCAP).‏ ‎‡9 1‏
919 ‎‡a lungcancerscreeningthebalancebetweenharmandbenefit‏ ‎‡A Lung Cancer Screening: The Balance between Harm and Benefit‏ ‎‡9 1‏
919 ‎‡a microalbuminuriaandhypoxemiainpatientswithchronicobstructivepulmonarydisease‏ ‎‡A Microalbuminuria and hypoxemia in patients with chronic obstructive pulmonary disease‏ ‎‡9 1‏
919 ‎‡a multicomponentindicestopredictsurvivalincopdthecocomicsstudy‏ ‎‡A Multicomponent indices to predict survival in COPD: the COCOMICS study.‏ ‎‡9 1‏
919 ‎‡a powerofoutcomemeasurementstodetectclinicallysignificantchangesinpulmonaryrehabilitationofpatientswithcopd‏ ‎‡A Power of outcome measurements to detect clinically significant changes in pulmonary rehabilitation of patients with COPD.‏ ‎‡9 1‏
919 ‎‡a prevalenceofpersistentbloodeosinophiliarelationtooutcomesinpatientswithcopd‏ ‎‡A Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD.‏ ‎‡9 1‏
919 ‎‡a prognosticassessmentincopdwithoutlungfunctionthebae500indices‏ ‎‡A Prognostic assessment in COPD without lung function: the B-AE-D indices.‏ ‎‡9 1‏
919 ‎‡a prognosticevaluationofcopdpatientsgold2011versusbodeandthecopdcomorbidityindexcote‏ ‎‡A Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE.‏ ‎‡9 1‏
919 ‎‡a prognosticvalidationusinggesepoc2017severitycriteria‏ ‎‡A Prognostic Validation Using GesEPOC 2017 Severity Criteria‏ ‎‡9 1‏
919 ‎‡a prospectivecomparisonofnoninvasiveriskmarkersofmajorcardiovasculareventsincopdpatients‏ ‎‡A Prospective comparison of non-invasive risk markers of major cardiovascular events in COPD patients‏ ‎‡9 1‏
919 ‎‡a pulmonaryarterialenlargementpredictslongtermsurvivalincopdpatients‏ ‎‡A Pulmonary arterial enlargement predicts long-term survival in COPD patients.‏ ‎‡9 1‏
919 ‎‡a redefiningcutpointsforhighsymptomburdenoftheglobalinitiativeforchronicobstructivelungdiseaseclassificationin18577patientswithchronicobstructivepulmonarydisease‏ ‎‡A Redefining Cut-Points for High Symptom Burden of the Global Initiative for Chronic Obstructive Lung Disease Classification in 18,577 Patients With Chronic Obstructive Pulmonary Disease.‏ ‎‡9 1‏
919 ‎‡a relationshipbetweenazithromycinsusceptibilityandadministrationefficacyfornontypeablehaemophilusinfluenzaerespiratoryinfection‏ ‎‡A Relationship between azithromycin susceptibility and administration efficacy for nontypeable Haemophilus influenzae respiratory infection‏ ‎‡9 1‏
919 ‎‡a responsetoexploringtheimpactofscreeningwithlowdosectonlungcancermortalityinmildtomoderatecopdpatients‏ ‎‡A Response to "Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients" ‏ ‎‡9 1‏
919 ‎‡a robuststandardizedquantificationofpulmonaryemphysemainlowdosectexams‏ ‎‡A Robust, standardized quantification of pulmonary emphysema in low dose CT exams‏ ‎‡9 1‏
919 ‎‡a sexdifferencesinmortalityinpatientswithcopd‏ ‎‡A Sex differences in mortality in patients with COPD.‏ ‎‡9 1‏
919 ‎‡a sexforcedexpiratoryvolumein1sdeclinebodyweightchangeand100reactiveproteinincopdpatients‏ ‎‡A Sex, forced expiratory volume in 1 s decline, body weight change and C-reactive protein in COPD patients‏ ‎‡9 1‏
919 ‎‡a shouldagebepartofmultidimensionalindicesofriskinchronicobstructivepulmonarydisease‏ ‎‡A Should age be part of multidimensional indices of risk in chronic obstructive pulmonary disease?‏ ‎‡9 1‏
919 ‎‡a simplifyingtheguidelinesthe10copdcommandments‏ ‎‡A Simplifying the guidelines: The 10 COPD commandments‏ ‎‡9 1‏
919 ‎‡a telomerelengthcopdandemphysemaasriskfactorsforlungcancer‏ ‎‡A Telomere length, COPD and emphysema as risk factors for lung cancer.‏ ‎‡9 1‏
919 ‎‡a telomereshorteningandacceleratedagingincopdfindingsfromthebodecohort‏ ‎‡A Telomere shortening and accelerated aging in COPD: findings from the BODE cohort.‏ ‎‡9 1‏
919 ‎‡a 6minwalkdistanceinhealthysubjectsreferencestandardsfrom7countries‏ ‎‡A The 6-min walk distance in healthy subjects: reference standards from seven countries‏ ‎‡9 1‏
919 ‎‡a 6minwalkingdistancelongtermfollowupinpatientswithcopd‏ ‎‡A The 6-min walking distance: long-term follow up in patients with COPD.‏ ‎‡9 1‏
919 ‎‡a effectofradiographicemphysemainassessinglungcancerrisk‏ ‎‡A The effect of radiographic emphysema in assessing lung cancer risk‏ ‎‡9 1‏
919 ‎‡a globalburdenofpulmonarydiseasesmostprevalentproblemsandopportunitiesforimprovement‏ ‎‡A The Global Burden of Pulmonary Diseases: Most Prevalent Problems and Opportunities for Improvement‏ ‎‡9 1‏
919 ‎‡a importanceofsymptomsinthelongitudinalvariabilityofclustersincopdpatientsavalidationstudy‏ ‎‡A The importance of symptoms in the longitudinal variability of clusters in COPD patients: A validation study‏ ‎‡9 1‏
919 ‎‡a neutrophiltolymphocyteandplatelettolymphocyteratiosasbiomarkersforlungcancerdevelopment‏ ‎‡A The neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers for lung cancer development‏ ‎‡9 1‏
919 ‎‡a prevalenceofobstructivelungdiseaseinalungcancerscreeningcohortanalysisofthenationallungscreeningtrialamericancollegeofradiologyimagenetworkcohort‏ ‎‡A The Prevalence of Obstructive Lung Disease in a Lung Cancer Screening Cohort: Analysis of the National Lung Screening Trial-American College of Radiology Image Network Cohort‏ ‎‡9 1‏
919 ‎‡a progressionofchronicobstructivepulmonarydiseaseisheterogeneoustheexperienceofthebodecohort‏ ‎‡A The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort‏ ‎‡9 1‏
919 ‎‡a timetodesaturationinthe6minwalkingdistancetestpredicts24houroximetryincopdpatientswithapo2between60and70mmhg‏ ‎‡A Time to desaturation in the 6-min walking distance test predicts 24-hour oximetry in COPD patients with a PO2 between 60 and 70mmHg‏ ‎‡9 1‏
919 ‎‡a tnfa863polymorphismisassociatedwithareducedriskofchronicobstructivepulmonarydiseaseareplicationstudy‏ ‎‡A TNFA-863 polymorphism is associated with a reduced risk of Chronic Obstructive Pulmonary Disease: A replication study‏ ‎‡9 1‏
919 ‎‡a trabecularbonescoreinactiveorformersmokerswithandwithoutcopd‏ ‎‡A Trabecular bone score in active or former smokers with and without COPD‏ ‎‡9 1‏
919 ‎‡a whatpulmonologiststhinkabouttheasthmacopdoverlapsyndrome‏ ‎‡A What pulmonologists think about the asthma-COPD overlap syndrome‏ ‎‡9 1‏
943 ‎‡a 201x‏ ‎‡A 2017‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 SUDOC|066991714‏
996 ‎‡2 SUDOC|035040688‏
996 ‎‡2 ISNI|000000005944845X‏
996 ‎‡2 LC|n 2002098544‏
996 ‎‡2 BNCHL|10000000000000000107077‏
996 ‎‡2 LC|n 85806499‏
996 ‎‡2 BNF|16558811‏
996 ‎‡2 BNE|XX5465820‏
996 ‎‡2 BNC|981058516704506706‏
996 ‎‡2 LC|nb 98033388‏
996 ‎‡2 BNE|XX1188864‏
996 ‎‡2 BNE|XX5705759‏
996 ‎‡2 DNB|1057344982‏
996 ‎‡2 LC|ns2014001748‏
996 ‎‡2 LC|ns2011001746‏
996 ‎‡2 DNB|1053072554‏
996 ‎‡2 PLWABN|9814024545705606‏
996 ‎‡2 ISNI|0000000401713600‏
996 ‎‡2 DNB|136147844‏
996 ‎‡2 LC|no2006048612‏
996 ‎‡2 ISNI|0000000001083662‏
996 ‎‡2 ISNI|0000000073418484‏
996 ‎‡2 ISNI|0000000051551874‏
996 ‎‡2 BNE|XX897618‏
996 ‎‡2 LC|no2018068657‏
996 ‎‡2 ISNI|0000000121432986‏
996 ‎‡2 BNE|XX1040723‏
996 ‎‡2 J9U|987007426574505171‏
996 ‎‡2 ISNI|0000000084164010‏
996 ‎‡2 BNE|XX1030768‏
996 ‎‡2 ISNI|0000000060915828‏
996 ‎‡2 ISNI|0000000107712025‏
996 ‎‡2 ISNI|0000000060319110‏
996 ‎‡2 ISNI|0000000408271753‏
996 ‎‡2 ISNI|0000000080053591‏
996 ‎‡2 LC|ns2013003002‏
996 ‎‡2 SUDOC|066013720‏
996 ‎‡2 NTA|375039295‏
996 ‎‡2 BNE|XX5397033‏
996 ‎‡2 DNB|1064588662‏
996 ‎‡2 PTBNP|217247‏
996 ‎‡2 LC|ns2013001631‏
996 ‎‡2 DNB|1057341819‏
996 ‎‡2 SUDOC|131073036‏
996 ‎‡2 BNC|981058612228306706‏
996 ‎‡2 BNE|XX1310925‏
996 ‎‡2 BNE|XX1781451‏
996 ‎‡2 BNCHL|10000000000000000069143‏
996 ‎‡2 BNC|981058528668506706‏
996 ‎‡2 ISNI|000000010043013X‏
996 ‎‡2 LC|n 92101874‏
996 ‎‡2 LC|nb2005011542‏
996 ‎‡2 ISNI|0000000044938894‏
996 ‎‡2 LC|n 2003048397‏
996 ‎‡2 BNCHL|10000000000000000134826‏
996 ‎‡2 LC|n 2007069566‏
996 ‎‡2 J9U|987007345263905171‏
996 ‎‡2 LC|ns2012005335‏
996 ‎‡2 LC|no 94021363‏
996 ‎‡2 LC|no 98078975‏
996 ‎‡2 BNF|13744562‏
996 ‎‡2 NLA|000061541731‏
996 ‎‡2 LC|ns2013000873‏
996 ‎‡2 SUDOC|152862412‏
996 ‎‡2 ISNI|0000000117742009‏
996 ‎‡2 DNB|114640770X‏
996 ‎‡2 ISNI|0000000061090717‏
996 ‎‡2 PLWABN|9811724166705606‏
996 ‎‡2 LC|n 93107905‏
996 ‎‡2 ISNI|0000000087051070‏
996 ‎‡2 LC|nb2009027776‏
996 ‎‡2 ISNI|0000000001274071‏
996 ‎‡2 DNB|133006328‏
996 ‎‡2 LC|ns2011001949‏
996 ‎‡2 LC|no 98026822‏
996 ‎‡2 DNB|1056620447‏
996 ‎‡2 BAV|495_181817‏
996 ‎‡2 LC|no2014125371‏
996 ‎‡2 ISNI|0000000053912792‏
996 ‎‡2 BNE|XX1162137‏
996 ‎‡2 ISNI|0000000068100834‏
996 ‎‡2 LC|no2013034163‏
996 ‎‡2 ISNI|000000005924836X‏
996 ‎‡2 BNCHL|10000000000000000866413‏
996 ‎‡2 RERO|A012071925‏
996 ‎‡2 LC|n 94015880‏
996 ‎‡2 LC|no2018091119‏
996 ‎‡2 SUDOC|120162199‏
996 ‎‡2 BNF|16973307‏
996 ‎‡2 BNE|XX1577604‏
996 ‎‡2 SUDOC|033315345‏
996 ‎‡2 DNB|1112337601‏
996 ‎‡2 BNF|16620711‏
996 ‎‡2 BNE|XX1721051‏
996 ‎‡2 NTA|307981363‏
996 ‎‡2 DNB|112555276X‏
996 ‎‡2 DNB|1089781296‏
996 ‎‡2 LC|n 2010027205‏
996 ‎‡2 ISNI|0000000078257894‏
996 ‎‡2 LC|n 2011028651‏
996 ‎‡2 LC|n 86869124‏
996 ‎‡2 BNE|XX6517693‏
996 ‎‡2 ISNI|0000000066337520‏
996 ‎‡2 LC|n 99022813‏
996 ‎‡2 SUDOC|130897019‏
996 ‎‡2 SUDOC|115260625‏
996 ‎‡2 LC|no2015134221‏
996 ‎‡2 SUDOC|134236793‏
996 ‎‡2 BNE|XX1240974‏
996 ‎‡2 NTA|168669897‏
996 ‎‡2 LC|n 2016068176‏
996 ‎‡2 PTBNP|1496782‏
996 ‎‡2 SUDOC|170409872‏
996 ‎‡2 LC|n 93023682‏
996 ‎‡2 LC|ns2011001235‏
996 ‎‡2 J9U|987007330159505171‏
996 ‎‡2 BNC|981058514327206706‏
996 ‎‡2 BNE|XX825767‏
996 ‎‡2 BNE|XX5433310‏
996 ‎‡2 ISNI|0000000072454029‏
996 ‎‡2 BNC|981061093964406706‏
996 ‎‡2 SUDOC|236638343‏
996 ‎‡2 BNE|XX1455376‏
996 ‎‡2 ISNI|000000002846561X‏
996 ‎‡2 LC|ns2021002706‏
996 ‎‡2 SUDOC|177389710‏
996 ‎‡2 BNC|981058530827106706‏
996 ‎‡2 NYNYRILM|32609‏
996 ‎‡2 DNB|1202732615‏
996 ‎‡2 PLWABN|9810650798105606‏
996 ‎‡2 DNB|143298712‏
996 ‎‡2 BNCHL|10000000000000000820967‏
996 ‎‡2 LC|no 00022631‏
996 ‎‡2 LC|n 2014034285‏
996 ‎‡2 ISNI|0000000059294868‏
996 ‎‡2 BNE|XX5437745‏
996 ‎‡2 BNC|981058610603806706‏
996 ‎‡2 LC|n 85087728‏
996 ‎‡2 ISNI|0000000059317185‏
996 ‎‡2 ISNI|0000000076716794‏
996 ‎‡2 DNB|138388830‏
996 ‎‡2 BNE|XX835070‏
996 ‎‡2 BNE|XX1791011‏
996 ‎‡2 LC|no2004000519‏
996 ‎‡2 PLWABN|9810542392505606‏
996 ‎‡2 NSK|000611132‏
996 ‎‡2 RERO|A005714359‏
996 ‎‡2 NUKAT|n 2017075671‏
996 ‎‡2 DNB|1157280412‏
996 ‎‡2 PLWABN|9810699837705606‏
996 ‎‡2 ISNI|000000005032424X‏
996 ‎‡2 LC|no2006069951‏
996 ‎‡2 BNE|XX1106461‏
996 ‎‡2 LC|ns2021000372‏
996 ‎‡2 LC|n 85092380‏
996 ‎‡2 BNE|XX1166393‏
996 ‎‡2 LC|no2024138177‏
996 ‎‡2 LC|no2010169902‏
996 ‎‡2 LC|n 85198243‏
996 ‎‡2 BNE|XX5153416‏
996 ‎‡2 DNB|1208850466‏
996 ‎‡2 SUDOC|271067705‏
996 ‎‡2 LC|nb2013024050‏
996 ‎‡2 DNB|105775952X‏
996 ‎‡2 LC|n 98084031‏
996 ‎‡2 ISNI|0000000383413718‏
996 ‎‡2 ISNI|000000007063865X‏
996 ‎‡2 ISNI|0000000079735341‏
996 ‎‡2 ISNI|0000000409333178‏
996 ‎‡2 LC|n 93077588‏
996 ‎‡2 BNE|XX1720664‏
996 ‎‡2 LC|n 50036793‏
996 ‎‡2 DNB|1056246111‏
996 ‎‡2 BNF|12572553‏
996 ‎‡2 ISNI|0000000118735951‏
996 ‎‡2 ISNI|0000000072287099‏
996 ‎‡2 ISNI|0000000078075783‏
996 ‎‡2 ISNI|0000000370832761‏
996 ‎‡2 SUDOC|258257202‏
996 ‎‡2 BNC|981060929701606706‏
996 ‎‡2 ISNI|0000000068294288‏
996 ‎‡2 DNB|143579258‏
996 ‎‡2 LC|n 2009042012‏
996 ‎‡2 LC|no2010181573‏
996 ‎‡2 PTBNP|249502‏
996 ‎‡2 SUDOC|031350542‏
996 ‎‡2 BNF|15584396‏
996 ‎‡2 LC|no2022093042‏
996 ‎‡2 LC|n 85189640‏
996 ‎‡2 BNCHL|10000000000000000249936‏
996 ‎‡2 SUDOC|228918456‏
996 ‎‡2 PLWABN|9810703186105606‏
996 ‎‡2 ISNI|0000000395103784‏
996 ‎‡2 BNC|981058611593206706‏
996 ‎‡2 LC|ns2023001660‏
996 ‎‡2 LC|nb2014026577‏
996 ‎‡2 BNE|XX5475370‏
996 ‎‡2 SUDOC|139255699‏
996 ‎‡2 ISNI|0000000118299643‏
996 ‎‡2 LC|ns2021003235‏
996 ‎‡2 DNB|1274485371‏
996 ‎‡2 BNE|XX6479558‏
996 ‎‡2 LC|no2013044469‏
996 ‎‡2 BNCHL|10000000000000000084864‏
996 ‎‡2 CAOONL|ncf10529105‏
996 ‎‡2 BNE|XX4685865‏
996 ‎‡2 CAOONL|ncf11853547‏
996 ‎‡2 ISNI|0000000420369809‏
996 ‎‡2 BNE|XX6232150‏
996 ‎‡2 SUDOC|188816771‏
996 ‎‡2 BNE|XX1455334‏
996 ‎‡2 ISNI|0000000459660441‏
996 ‎‡2 BNF|16242355‏
996 ‎‡2 NTA|132136198‏
996 ‎‡2 LC|no2003049915‏
996 ‎‡2 DNB|1056419466‏
996 ‎‡2 SUDOC|200713736‏
996 ‎‡2 DNB|1056788798‏
996 ‎‡2 J9U|987007448037005171‏
996 ‎‡2 BNE|XX1143815‏
996 ‎‡2 DNB|1026519926‏
996 ‎‡2 NLR|RU NLR AUTH 770250078‏
996 ‎‡2 ISNI|0000000045696567‏
996 ‎‡2 ISNI|0000000514185349‏
996 ‎‡2 BNF|14550616‏
996 ‎‡2 BNF|17057724‏
996 ‎‡2 BNE|XX4690788‏
996 ‎‡2 DNB|1055587543‏
996 ‎‡2 BNE|XX1080481‏
996 ‎‡2 BNC|981058514443506706‏
996 ‎‡2 DNB|105621483X‏
996 ‎‡2 DE633|pe30108441‏
996 ‎‡2 ISNI|0000000048673731‏
996 ‎‡2 BIBSYS|8041876‏
996 ‎‡2 ISNI|0000000383767751‏
996 ‎‡2 ISNI|0000000061588507‏
996 ‎‡2 LC|nr 95033529‏
996 ‎‡2 LC|nb2011005508‏
996 ‎‡2 PTBNP|1531928‏
996 ‎‡2 ISNI|0000000359724719‏
996 ‎‡2 RERO|A021694085‏
996 ‎‡2 BNCHL|10000000000000000072941‏
996 ‎‡2 LC|no2009098187‏
996 ‎‡2 DNB|135613523‏
996 ‎‡2 RERO|A025914651‏
996 ‎‡2 BNE|XX1006624‏
996 ‎‡2 LC|no2010061177‏
996 ‎‡2 BNC|981058511634806706‏
996 ‎‡2 BNC|981058518367106706‏
996 ‎‡2 SUDOC|256686009‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏